回盛生物(300871.SZ):報告期內取得了7個寵物產品批文,極大擴展了寵物產品線
格隆匯8月6日丨回盛生物(300871.SZ)在投資者關係中表示,寵物藥品板塊屬於公司重點發展方向之一。公司調整資源分配,加大在寵物藥品研發及市場渠道建設方面投入,已擁有獨立、專業化的寵物藥品研發團隊,報告期內取得了7個寵物產品批文,極大擴展了寵物產品線。公司寵物藥品主要涉及寵物驅蟲類、解熱鎮痛類、皮膚用藥、內科疾病類及功能性保健品等細分領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.